Brief: Arch Biopartners Receives Permission From US FDA To Proceed With Phase II Acute Kidney Injury Trial
27/06/2023 13:55
June 27 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS RECEIVES PERMISSION FROM U.S. FDA TO
PROCEED
WITH PHASE II ACUTE KIDNEY INJURY TRIAL
* ARCH BIOPARTNERS INC - CS-AKI TRIAL HAS PLANS TO RECRUIT
UP TO
240 PATIENTS
* ARCH BIOPARTNERS INC - PATIENT RECRUITMENT FOR CS-AKI
TRIAL IS
EXPECTED TO BEGIN IN FALL OF 2023
Source text for Eikon: ID:nGNX3spfrg
Further company coverage: ARCH.V
((reuters.briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide